Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme in the family of proprotein convertases implicated in lipid metabolism and is a significant genetic risk factor in cardiovascular diseases among various populations.
Aim of the Study:
This study explored the correlation between the alleles of the rs505151 (E670G) locus of the PCSK9 gene and its expression levels with coronary artery disease (CAD) risk in Egyptian patients with type 2 diabetes mellitus (T2DM).
Subjects and Methods:
A case-control study was performed on 112 lean subjects compared to 100 T2DM patients without CAD and 84 T2DM patients with CAD to investigate the relationships among PCSK9 expression levels, the E670G (rs505151) gene variant, lipid concentrations, and CAD risk in an Egyptian diabetic population. A restriction fragment length polymorphism-polymerase chain reaction (PCR) assay was used to assess the gene polymorphism, and PCSK9 mRNA expression was determined by quantitative real-time PCR.
Results:
The prevalence of the E670G (rs505151) AG genotype in diabetics with CAD was significantly greater than the other two groups. The PCSK9 gene expression levels in diabetics with CAD were significantly greater than the other two groups. G allele carriers (AG+GG) had a higher relative PCSK9 expression than A allele carriers.
Conclusion:
PCSK9 relative expression levels and the E670G (rs505151) AG genotype are CAD risk factors among Egyptian diabetics and are linked positively to the atherogenic index of plasma.
Get full access to this article
View all access options for this article.
References
1.
AhmadOS, MorrisJA, MujammamiM, et al. (2015) A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun, 6:7060.
2.
American Diabetes Association (2019). 15. Diabetes care in the hospital: standards of medical care in Diabetes-2019. Diabetes Care 42(Suppl, 1):S173-S181.
3.
AungL, YinRX, MiaoL, et al. (2011) The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis, 10:5.
4.
BaysHE, JonesPH, BrownWV, et al. (2014) National lipid association annual summary of clinical lipidology 2015. J Clin Lipidol, 8,(6 Suppl)::S1-S36.
5.
BaysHE, JonesPH, OrringerCE, et al. (2016) National lipid association annual summary of clinical lipidology 2016. J Clin Lipidol, 10,(1 Suppl)::S1-S43.
6.
BordicchiaM, SpannellaF, FerrettiG, et al. (2019) PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides. Int J Mol Sci, 20:245.
7.
BrouwersMC, TrouttJS, GreevenbroekMM, et al. (2011) Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis, 217:263-267.
8.
BuccoloG, DavidH (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin Chem, 19:476-482.
9.
CaiG, ShiG, XueS, et al. (2017) The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Med (Baltim), 96:e8058.
10.
CaiG, YuL, HuangZ, et al. (2018) Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population. Lipids Health Dis, 17:213.
11.
ChanDC, WattsGF, SomaratneR, et al. (2018) Comparative effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibition and statins on postprandial triglyceride-rich lipoprotein metabolism. Arterioscler Thromb Vasc Biol, 38:1644-1655.
12.
FerriN, TibollaG, PirilloA, et al. (2012) Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 220:381-386.
13.
FrieldewaldWT, LevyRI, FredricksonDS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18:499-502.
14.
FrohlichJ, DobiasovaM (2003) Fractional esterification rate of cholesterol and triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem, 4911:1873-1880.
15.
GlovaciD, FanW, WongND (2019) Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep, 21:21.
16.
HeXM, ChenL, WangTS, et al. (2016) E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China. Asian Pac J Trop Med, 9:172-176.
17.
HsuLA, TengMS, KoYL, et al. (2009) The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin Chem Lab Med, 47:154-158.
18.
HumphryRW, CameronA, GunnGJ (2004) A practical approach to calculate sample size for herd prevalence surveys. Prev Vet Med, 65:173-188.
19.
International Diabetes Federation (2019) IDF Diabetes Atlas. 2019, 9th edn. Brussels, Belgium. Available at: https://www.diabetesatlas.org
20.
IvanovaEA, MyasoedovaVA, MelnichenkoAA, et al. (2017) Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev, 2017:1273042.
21.
KaplanLA, Glucose K (1984) ClinChem. The C. V. Mosby Co., St Louis. Toronto, Princeton 1032-1036.
22.
KashyapS, KumarS, AgarwalV, et al. (2018) The association of polymorphic variants, rs2267788, rs1333049 and rs2383207 with coronary artery disease, its severity and presentation in North Indian population. Gene, 648:89-96.
23.
KoshyL, AnjuAL, HarikrishnanS, et al. (2017) Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays. Mol Biol Rep, 44:97-108.
24.
KotowskiIK, PertsemlidisA, LukeA, et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet, 78:410-422.
25.
LiWJ, YinRX, CaoXL, et al. (2018) DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke. Lipids Health Dis, 17:30.
26.
LivakKJ, SchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods, 25:402-408.
27.
MbikayM, SiroisF, MayneJ, et al. (2010) PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett, 584:701-706.
28.
Meireles-BrandãoJA, Meireles-BrandãoLR, CoelhoR, et al. (2019) Lipoprotein(a) in the evaluation of cardiovascular risk in the Portuguese population. Acta Med Port, 32:202-207.
29.
MomtaziAA, BanachM, PirroM, et al. (2017) PCSK9 and diabetes: is there a link?. Drug Discov Today, 22:883-895.
30.
Naito HK (1984a) Cholesterol. ClinChem. TheC.V. MosbyCo., StLouis, TorontoPrinceton; pp. 1194-11206 and 437.
31.
Naito HK (1984b) High-density lipoprotein (HDL) cholesterol. In: Kaplan A, et al. (eds) Clin Chem. The C.V. Mosby Co. St Louis, Toronto, Princeton, pp. 1207-1213 and 437.
32.
NaseriF, MoslemiE, EsfahaniK (2017) The communication of rs (505151) with amount of PCSK9 gene expression in cardiovascular disease. Indo Am J Pharm Sci, 4:3583-3588.
33.
NoseD, ShigaY, UedaY, et al. (2019) Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart Vessels, 34:19-28.
34.
QiuC, ZengP, LiX, et al. (2017) What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis?. Lipids Health Dis, 16:111.
35.
RashidS, TavoriH, BrownPE, et al. (2014) Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and independent mechanisms. Circulation, 130:431-441.
36.
RayKK, ColhounHM, SzarekM, et al. (2019a) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomized controlled trial. Lancet Diabetes Endocrinol, 7:618-628.
37.
RayKK, Del-PratoS, Müller-WielandD, et al. (2019b) Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol, 18:149.
38.
SaeediP, PetersohnI, SalpeaP, et al. (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:10, 7843.
39.
ShapiroMD, FazioS (2017) PCSK9 and atherosclerosis—lipids and beyond. J Atheroscler Thromb, 24:462-472.
40.
SlimaniA, HariraY, TrabelsiI, et al. (2014) Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort. J Mol Neurosci, 53:150-157.
41.
SteffesM, ClearyP, GoldsteinD, et al. (2005) Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Clin Chem, 51:753-758.
42.
TangY, LiSL, HuJH, et al. (2020) Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovasc Diabetol, 19:33.
43.
WanH, GumbinerB, JohT, et al. (2017) Effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with Bococizumab on lipoprotein particles in Hypercholesterolemic subjects. Clin Ther, 39:2243-2259.e5.
44.
WangY, YeJ, LiJ, et al. (2016) Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc Diabetol, 15:19.
45.
YangSH, XuRX, CuiCJ, et al. (2018) Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol, 17:48.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
